Genetic Signatures signs up
Wednesday, 22 October, 2008
Privately held Sydney biotech Human Genetic Signatures has signed a licensing agreement with US diagnostics specialist ProGen Tech to develop assays for pathogens such as MRSA and Clostridium difficile.
The assays will be integrated into ProGen Tech’s Entura nucleic acid purification system.
Human Genetic Signatures’ technology is called 3base, which is designed to simplify the genomes of microbial targets to aid detection. The company has also developed a DNA methylation analysis methodology called MethylEasy.
ProGen Tech hopes to present manual assays to the US FDA next year, followed by a fully automated version in 2010.
The equipment is aimed at the molecular and clinical diagnostics markets.
Depression impacts energy at a cellular level, researchers find
Depression symptoms may be rooted in fundamental changes in the way brain and blood cells use...
Are discarded peanut shells the affordable and sustainable path to graphene?
Australian researchers have produced small quantities of high-quality graphene via a new process...
Aussie biotech to manufacture mRNA paediatric brain cancer vaccines
A Queensland-based biotechnology company will manufacture personalised mRNA paediatric brain...
